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Abstract
A model based on a specific phantom, called QuAArC, has been designed for the evaluation
of planning and verification systems of complex radiotherapy treatments, such as volumetric
modulated arc therapy (VMAT). This model uses the high accuracy provided by the Monte
Carlo (MC) simulation of log files and allows the experimental feedback from the high spatial
resolution of films hosted in QuAArC. This cylindrical phantom was specifically designed to
host films rolled at different radial distances able to take into account the entrance fluence
and the 3D dose distribution. Ionization chamber measurements are also included in the
feedback process for absolute dose considerations. In this way, automated MC simulation
of treatment log files is implemented to calculate the actual delivery geometries, while the
monitor units are experimentally adjusted to reconstruct the dose-volume histogram (DVH)
on the patient CT. Prostate and head and neck clinical cases, previously planned with
Monaco and Pinnacle treatment planning systems and verified with two different commercial
systems (Delta4 and COMPASS), were selected in order to test operational feasibility of the
proposed model. The proper operation of the feedback procedure was proved through the
achieved high agreement between reconstructed dose distributions and the film measure-
ments (global gamma passing rates > 90% for the 2%/2 mm criteria). The necessary discre-
tization level of the log file for dose calculation and the potential mismatching between
calculated control points and detection grid in the verification process were discussed.
Besides the effect of dose calculation accuracy of the analytic algorithm implemented in
treatment planning systems for a dynamic technique, it was discussed the importance of the
detection density level and its location in VMAT specific phantom to obtain a more reliable
DVH in the patient CT. The proposed model also showed enough robustness and efficiency
to be considered as a pre-treatment VMAT verification system.
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R, Perucha M, Jiménez-Ortega E, et al. (2016) 3D
VMAT Verification Based on Monte Carlo Log File
Simulation with Experimental Feedback from Film
Dosimetry. PLoS ONE 11(11): e0166767.
doi:10.1371/journal.pone.0166767
Editor: Qinghui Zhang, North Shore Long Island
Jewish Health System, UNITED STATES
Received: July 1, 2016
Accepted: November 3, 2016
Published: November 21, 2016
Copyright: © 2016 Barbeiro et al. This is an open
access article distributed under the terms of the
Creative Commons Attribution License, which
permits unrestricted use, distribution, and
reproduction in any medium, provided the original
author and source are credited.
Data Availability Statement: All relevant data are
within the paper and its Supporting Information
files.
Funding: This work was supported by the Spanish
Ministry of Science and Technology (SAF2011-
27116; IPT-2011-1480-900000) and the European
Regional Development Fund. The funders had no
role in study design, data collection and analysis,
decision to publish, or preparation of the
manuscript.
Introduction
The complexity of intensity modulated treatments in radiotherapy is increasing significantly,
especially in rotational dynamic techniques, such as volumetric modulated arc therapy
(VMAT), in pursuit of delivery demanding dose distributions in shorter treatment times with
fewer monitor units (MUs) than conventional intensity modulated radiotherapy (IMRT) [1].
Nevertheless, the completely dynamic implementation involves an added complexity to the
planning, since additionally to the dynamic multi-leaf collimator (MLC) movement, the dose
rate and gantry motion have to be synchronized during irradiation [2]. New uncertainties
about this dynamic nature of the VMAT delivery increase the complexity of the associated
quality assurance (QA) [3–5]. Therefore, new QA systems are continuously becoming avail-
able, while also there exist no clear guidelines and criteria for the accuracy required.
It could be stated that, unlike static field IMRT, all systems implemented for VMAT QA
have to face two main sources of uncertainty: one related to the dose calculation accuracy com-
mon to any modulated technique, and other linked to the continuous delivery of a discrete
calculation.
On one hand, the dose calculation accuracy is a double problem concerning the consider-
ation of patient heterogeneities and also the beam modifiers contribution to the final dose. On
the theoretical definition of VMAT presented by Otto [2], Monte Carlo (MC) was already pro-
posed as an effective and necessary tool [6, 7]. MC particle transport simulation is recognized
for its higher accuracy to model linac heads, especially in non-standard dosimetric conditions,
like the ones involved in VMAT treatments. In this way, it is possible to know the dose contri-
bution of the scattered and transmitted radiation through the beam modifiers, which are
expected to play a relevant role in a dynamic modulated technique, such as VMAT. Still con-
sidering the challenge of achieving operating times for clinical practice, the explicit and accu-
rate calculation provided by MC method is suitable for assessing the real VMAT capabilities.
On the other hand, the accuracy of the dose distribution can also be compromised by
potential differences between the discrete apertures and corresponding MUs proposed by the
TPS, and those continuously delivered by the linac. Algorithms implemented in TPSs use dis-
crete series of control points (CPs) to optimize VMAT treatments in such a way that the qual-
ity of the final solution depends on the number of these starting points [8]. In spite of the
dynamic behavior is correctly modelled in some TPSs, even using Monte Carlo dose calcula-
tion as Monaco1, most planning systems make an approximation by summing doses calcu-
lated at the discrete CP and not in between [9]. This means that the MUs optimized for a fixed
aperture shape are actually delivered with different shapes at different angles [10]. For this rea-
son, the linac log files registered during the irradiation are usually considered to compute the
delivered dose distribution. The considerable data recorded in log file requires a reduction of
the actual dynamic event for the subsequent calculation. This reduction imposes a level of dis-
cretization that can be equivalent to the considered level in the planning system [11, 12], but it
seems reasonable to think the larger the number of CPs calculated from the log file, the better
this approximation is.
In order to cover both type of uncertainties commented above, some works proposed MC
simulation of linac log files recorded during treatment delivery [6, 13, 14]. The dose distribu-
tion discrepancy introduced between the discretized plan and the continuous delivery was
assessed by incorporating DynaLog files into MC simulations for RapidArc QA [6]. For that
work, a new DOSXYZnrc source [15] was used to compute the dose distribution, by consider-
ing a continuous variable beam configuration, through sampling-based methods. This
approach reached simulation times for routine clinical applications, although the required sta-
tistical uncertainty was only ensured in the high dose voxels. It could be efficient for treatment
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verification but not suitable to assess one of the supposed benefits of VMAT associated to the
reduction of integral radiation dose to the rest of the body [1]. Furthermore, this approach
may over-simplify VMAT delivery in certain parts of the arc where changes in gantry speed
are larger than in others and the variable dose rate could not be considered with the same accu-
racy. This could be important to assess the potential radiobiological influence of different dose
rates during VMAT delivery. Because of these considerations, other works incorporate differ-
ent methods to represent the linac motion with a VMAT delivery emulator [14], where impor-
tant differences were found between static and continuous dose calculation, as it was
differently reported by Teke et al. [6]. It is important to remark that different results could be
also linked to the type of verification systems implemented to assess the impact of VMAT
delivery efficiency, since dose experimental measurements should be used to support the dose
calculation from log files, or even from an emulator. Actually, these approaches showed only
an accurate second check of dose calculation based on MC by considering the delivered geo-
metrical parameters, since no experimental measurements were directly included to estimate
the actual dose dynamically delivered to the patient. For this purpose, the discretization degree
and the accuracy used in dose calculation would be sensible to the efficiency of detectors and
their locations inside VMAT systems.
Several studies have stated poor correlation between the most commonly employed gamma
index for comparing dose distributions in a phantom and dose errors in the patient anatomy
[16, 17]. In addition, this gamma index can be misleading and insensitive to clinically relevant
dosimetric errors. Therefore, dose-volume histogram (DVH)-based metrics should also be
examined, especially in regions with high-dose gradients [18]. Apart from singular solutions
for own use [19], only a limited number of measurement-based 3D anatomy dose QA devices
are commercially available: 3DVH (Sun Nuclear Corporation), COMPASS (IBA Dosimetry),
Delta4DVH Anatomy (ScandiDos). These are associated with diode arrays with different
geometries, capable of provide 3D dose verifications [20, 21], or planar measurements
obtained by an ion chamber array mounted on the gantry [22]. Detector arrays limited by
their spatial resolution, may affect the verification results due to under-sampling effects [23].
The Delta4DVH Anatomy and COMPASS use independent dose calculation algorithms,
which calculate the dose to the patient using the energy fluence. The 3DVH does not recalcu-
late the dose, but only perturbs the TPS patient planned dose to account for known errors
measured in the conventional QA [24]. In this case, the limitations related to the dose calcula-
tion engine are still present.
An accurate 3D verification of VMAT with high calculation resolution, based on the infor-
mation provided by the log file, demands the implementation of an experimental validation
with high detection degree in order to minimize potential spatial mismatching between calcu-
lation and measurements. Although the data analysis process makes film dosimetry a less pop-
ular method for QA compared to previously mentioned verification systems, the high spatial
resolution, minor energy dependence, and near tissue-equivalence provided by the radiochro-
mic films, are well suited for VMAT QA purposes. The use of film dosimetry in a 3D spatial
distribution was already proposed [25, 26], but the measurements were not managed to recon-
struct the 3D dose distribution in the patient anatomy.
In order to evaluate and address the limitations inherent to VMAT verification systems dis-
cussed above, we present a model based on the MC simulation of log files with experimental
feedback from film dosimetry. This proposal is focused to provide a tool for general VMAT
evaluation, more than to present another alternative for clinical routine, although the model
could be also used for it. The sampling of CPs is performed according to dose rate changes and
is able to consider different discretization levels. The corresponding MUs are experimentally
obtained from radiochromic films rolled at different radial distances in a cylindrical phantom,
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called QuAArC, specifically designed to reconstruct a DVH by considering an approximation
of entrance fluence, 3D relative dose distribution and absolute dose. The high detection density
provided by the film ensures the agreement between the considered CP and detector location.
Materials and Methods
QuAArC system
A cylindrical shape PMMA phantom (physical density 1.19 g/cm3), consisting of a set of two
concentric cylinders, was specifically designed to host radiochromic films rolled at different
radial distances from the isocenter, for a 3D and continuous dosimetric verification. As it can
be seen in Fig 1, different radial distances were selected to obtain dose distributions close to the
treatment site and also estimation of fluence at the beam entrances in the phantom. In order to
ensure the films are correctly placed, the cylinders size was thought to be equal to the length of
films. Moreover, the phantom has several marked reference lines to know the exact film loca-
tion during the setup mounting and positioning on the treatment table with the usual laser sys-
tem (Fig 1). Other components allow a configuration prepared for axial or coronal films and
dose point measurements with several types of ion chambers at different locations (Fig 1).
Besides the PMMA components, it also includes a set of cork cylinders and inserts to simulate
lung or air-like cavities. In order to consider the verification of several treatment regions,
QuAArC phantom comprises two different setups: one with dimensions of 30 cm diameter and
30 cm length (big setup), and the other with 20 cm diameter and 28 cm length (small setup).
For QuAArC verification of real plans, Gafchromic EBT3 films with dimensions of 20.3 x
25.4 cm2 were rolled around the outer cylinder, at 1 cm depth (2 films), and the inner cylinder,
at 6 cm depth (1 film) in the phantom, from now on the outer and inner film scrolls, respec-
tively. Absolute dose measurements with a CC04 ion chamber (IBA Dosimetry) placed at the
isocenter for each treatment in QuAArC phantom were also performed. Chamber reading con-
version to dose was made following the IAEA TRS-398 protocol, and then compared to the cor-
responding absorbed dose to water calculated by MC in the PMMA QuAArC phantom. The
irradiated films were processed following a specific protocol, which included the characteriza-
tion procedure of the scanner-film system, in order to minimize the related uncertainties. All
films were scanned at least 12h after exposure, using an Epson Expression 10000 XL (Seiko
Epson Corp.) flatbed scanner at a resolution of 75 dpi and a depth of 48-bit RGB, without apply-
ing any color correction. The films were all scanned in the portrait orientation at the center of
the scanner to use its optimum part, which was determined through the characterization pro-
cess. A calibration curve for a single batch of EBT3 and 6MV photon beams was obtained by
irradiating sixteen pieces of 5 × 6 cm2 from the same film. The pieces were individually irradi-
ated with a 10 x 10 cm2 beam in reference conditions, with doses ranging from 0 to 400 cGy, for
an appropriate characterization of the film response behavior, including more than 12 points as
proposed by Bouchard et al. [27]. Because of film scrolls normally would receive lower doses,
especially in outer films, than the films used in typical verifications, it was important to have an
exhaustive characterization of dose-response curve in the low-dose range. For the conversion of
the film pixel value into dose, a multichannel method was used [28], and also corrections for
the non-uniformity lateral dose dependence response of the scanner were applied to the three
channels (RGB). Although the same effect in the longitudinal scanner direction was also charac-
terized, corrections were not applied since it was found to be negligible.
MC simulation and discretization process of log files
For a QA model applied to VMAT evaluation, an automated MC simulation of the geometry
of every control point was implemented in an in-house developed Matlab program. Simulation
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parameters were extracted from the log files recorded during the treatment delivery by means
of specific software written in C++ developed by our group. This software allows the commu-
nication with the Elekta linac in real time, under the iCom Protocol, and is able to record all
the CP parameters every 0.25s or 1s during beam on or beam off, respectively. This 4 Hz
recording rate is similar to other tools implemented for log file analysis in Elekta linacs [11].
The analysis and comparison of relevant delivery parameters can always be made without fur-
ther reduction of the data recorded in these log files. However, the data retrieved for MC simu-
lation and dose calculation from log files are dependent on the required discretization level.
The implementation used for QuAArC system applies a discretization method designed for
taking into account the relationship between changes in MUs and gantry motion for a higher
sampling rate when more significant changes are present in a specific sector of the arc. In this
way, the dose rate is intrinsically considered for the sampling process. Obviously, this process
does not lead to equi-spaced CPs along the arc. For this work the delivered parameters for MC
simulation were considered with more CPs describing the arc (fine log) than the one usually
presented in the DICOM-RT plan file from the TPS (coarse log). For the coarse discretization
level, after excluding CPs where there was no variation in cumulative MU, the actual
Fig 1. QuAArC phantom. Different setups of QuAArC phantom prototype (top) and the final PMMA phantom (bottom). On the top, the big setup is
depicted with radiochromic films rolled at two different radial distances. The independent inside part of the phantom is shown on the bottom, and
constitutes the small setup.
doi:10.1371/journal.pone.0166767.g001
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cumulative value at the end of each control point was retrieved along with the actual leaf posi-
tions and the corresponding gantry angle, recorded during that sampling time. In general, the
number of simulated CPs will be dependent on the original treatment plan and its complexity.
In particular, this number was about three times higher for the fine approach compared to the
coarse one for the evaluated plans in this work.
The EGSnrc Monte Carlo user code BEAMnrc [29] was used to simulate the 6 MV photon
beams from two Elekta linacs, Axesse and Synergy. The following BEAMnrc/EGSnrc transport
parameters were employed: NIST for bremsstrahlung cross sections; EXACT as boundary
crossing algorithm and PRESTA-II as electron-step algorithm; for bremsstrahlung angular
sampling, the leading term of Koch-Motz distributions was chosen; electron and photon cutoff
energies were 0.7 MeV (0.189 MeV kinetic energy) and 0.01 MeV, respectively. For all simula-
tions, electron range rejection with an energy cutoff of 2.0 MeV was implemented. For the MC
simulations of VMAT treatments, a phase-space data (PSD) file was first obtained from the
simulation of the corresponding linac head non-treatment dependent, in order to be used as
source for the transport simulation through the geometry of beam modifiers specific to each
case. The subsequent PSD files were obtained by means of the simulation of each CP geometry
considered from the log file and were scored at the exit of the corresponding linac head to be
used as inputs for the dose calculation in the patient.
To accurately simulate the beam modifiers contribution, MLC geometry was modelled
using the BEAMnrc MLCE component module. This linac model has been previously vali-
dated for other published works [30] by comparison with experimental measurements of pro-
files and depth dose distributions corresponding to several field sizes (ranging from
2.4x2.4cm2 to 16x21cm2) obtained with ionization chamber and semiconductor diode. These
results were achieved with a statistical uncertainty of less than 1%, and an agreement within
2% was obtained between experimental measurements and MC calculations. Furthermore,
experimental measurements with radiochromic film were included to validate inter and intra
leaf transmission with a nominal gap and a slight leaf bank tilt of the focused leaves.
All MC simulations were distributed on a cluster of four 12-core 2.19 GHz CPUs AMD
Opteron.
Dose processing in QuAArC and MU adjustment for 3D dose
reconstruction
The corresponding dose calculation was carried out from the phase-space files previously
obtained for each CP, by means of BEAMDOSE, an in-house DOSXYZnrc code modification.
This code allows knowing every aperture contribution to each voxel in order to score the indi-
vidual dose through each voxel of the phantom representing either a patient CT or a QA phan-
tom. Dose calculation was performed with a high resolution grid, consisting on 256 × 256
voxels per slice, for a fair comparison with film. For these simulations, particle transport
parameters were similar to those used for the BEAMnrc simulations, except the energy thresh-
old for electron transport ECUT, which was set to 0.512 MeV, considering the voxel size. The
number of histories used was selected to ensure the statistical uncertainty below 1% in the final
dose for all the voxels inside the treatment region. The same statistics was achieved indepen-
dently of the discretization level implemented by considering different number of history cases
according to the number of CPs from the log file. In order to process and evaluate the unusual
dose distribution in the irradiated film scrolls, specific in-house software was also developed in
Matlab, which incorporates the analysis of dose distributions, profiles, dose difference maps,
and 2D/3D gamma index. The cylindrical distribution of the films in the 3D dose cubic voxe-
lized matrix (1.25 x 1.25 x 1 mm3) demands a specific recruitment process based on
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interpolations each 0.5˚ between voxel values taken from the nearest neighbors in the three
axes. In order to take into account the disagreement between different coordinate systems, one
planar MC matrix was reconstructed for each, inner and outer scrolls, from 5 planar matrices
generated by shifting the isocenter to ± 1 pixel. In this way, we can assume that the uncertainty
location between MC scroll and film scroll was ± 1.25 mm, for the considered grid. During the
comparative analysis between both dose distributions, an efficient non-deformable mutual
information method was implemented in our software to account for small shifts or rotations
that could take place during the film processing.
In order to obtain an experimental DVH, a least-squares optimization method following
the expression (1) was implemented in our software, taking into account the measurements





kC  x   dk2
2
such that
A  x  b
Aeq  x ¼ beq





C is the MC dose matrix containing the individual CP contribution to each voxel; x is a MU
weight vector, considered as a percentage of MU change from either the initial solution calcu-
lated from the log file or the final proposed solution; d is the matrix composed by the films
dose matrices and the isocenter absolute dose measured with ion chamber; A and b are the lin-
ear inequality constraint to establish the tolerance of dose difference between MC dose and
measurements (considering both, positive and negative differences); Aeq and beq are the linear
equality constraints, specified as a vector and a scalar, respectively, which represent the original
MU weight vector from log file, and the total treatment MU; lb and ub represent the lower and
upper bounds for the solution x, allowing the control of the change level on the MU values
from log file to match the experimental value. In this process, the global contribution of each
individual CP to the whole treatment is assessed and adjusted according to the measurements.
The rolled films provide us measurements of fluence estimation (outer film scroll) and relative
dose contribution (inner film scroll) of the direct entrance, lateral overlapping, and the oppo-
site irradiation for the whole arc. The contribution of opposite irradiation present in these film
scrolls, it is not a handicap because it is considered in a global manner along the optimization
process. It is important to note that the values lb and ub are considered as a percentage of the
original MU corresponding to each CP in the log file. In this way, it is possible to accept only
relative small changes for each new MU during the iterations in the optimization process. The
latter in addition to a minimum tolerance of dose difference, makes possible to obtain experi-
mental values as a result of an average of the heterogeneity within the irradiated area in the
film corresponding just to one CP. Therefore, the adjustment is mainly performed by using
the contribution from lateral overlapping, what is directly related to the discretization effect.
This approach makes possible the study of the effect of considering several discretization
levels from the log file simulation, since deviations measurement caused by a mismatching
detection location can be overcome thanks to the high density detection inherent to film
dosimetry.
On the other hand, the control of parameters in this feedback process would also allow
obtaining a new proposal of a treatment plan with larger changes in MU values, but still in
accordance to the experimental measurements able to provide a final DVH on patient CT clin-
ically acceptable. This last operative option of our method was not evaluated for this work.
As a summary, a general flowchart representing the proposed model is shown in Fig 2.
3D VMAT Verification
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QuAArC system validation with clinical cases
As a proof of concept of our model, four clinical cases, corresponding to prostate and head
and neck (H&N) treatments were selected. For the real clinical application, these cases were
planned with two different commercial TPSs, Monaco, Elekta and Pinnacle, Philips, and veri-
fied with ScandiDos Delta4 and IBA COMPASS systems, respectively.
For the Monaco/Delta4 option, two cases with two different plans each one were evaluated.
A first solution for both cases (plan A), did not meet the acceptance criteria, which consisted
of more than 95% of the evaluated points with a global gamma index < 1, for 2.5% dose differ-
ence (DD) and 2mm distance to agreement (DTA) criterion and a dose threshold of 20%, in
the Delta4 detector planes. A second solution (plan B) was proposed for both cases, in order to
find solutions that meet these acceptance criteria when verified with Delta4. In particular, the
plan A for both cases, prostate and H&N, failed with a passing rate of 91.8% and 76.9%, respec-
tively, while the plan B passed with 95.6% and 99.6%, respectively.
From a pool of clinical cases, the prostate case was selected for this study due to the high
similarity between the DVHs presented by Monaco TPS solutions for both plans, A and B,
which consisted of a single arc VMAT treatment composed by 87 and 78 CPs, respectively.
The H&N case consisted of a boost phase treatment. In this case, a single arc VMAT plan with
93 CPs was the plan A, and the second plan proposed (plan B) was a static IMRT technique,
which did pass the Delta4 QA and was accepted for treatment. This IMRT plan, consisting of
34 segments distributed in 9 incidence angles (ranging from 205˚ to 180˚ CW), and it was spe-
cifically considered as a static example to check the correct implementation of our algorithm,
Fig 2. Flowchart describing the proposed model. Film measurements in QuAArC phantom are
implemented in a feedback process in order to adjust the MUs from the log file for reweighting the full MC
simulated CPs to obtain the final reconstructed DVH on patient CT.
doi:10.1371/journal.pone.0166767.g002
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since potential discrepancies between MC and the film scrolls generated by the discretization
process would not be present in this scenario.
For the Pinnacle/COMPASS option, also a prostate and H&N cases were selected, although
only two VMAT treatment plans were included, both having met the acceptance criteria.
These criteria were based on the DVHs comparison between Pinnacle TPS and COMPASS
solutions, through relevant dose metrics. These VMAT plans consisted of a single arc with 90
equi-spaced CPs treated with a hypofractionation scheme (3Gy/fx), for the prostate case, while
for the H&N case consisted of a double arc with a total of 180 equi-spaced CPs.
Results and Discussions
Effect of discretization level on treatment verification evaluated with
QuAArC
Potential effects of considering a different discretization level from the log files for MC simula-
tion in treatment verification was analyzed by comparison with the film scrolls irradiated in
the QuAArC phantom (Fig 3). These effects can be observed in the corresponding DVHs
experimentally reconstructed on the patient CT data (Fig 4(c)–4(f)) by means of the model
Fig 3. Effects of considering a different discretization level from the log files. Percent dose difference matrices of the inner film scroll
versus MC Log (left) and versus the corresponding QuAArC solution (right) for coarse discretization (top) and fine discretization (bottom),
corresponding to prostate VMAT plan B.
doi:10.1371/journal.pone.0166767.g003
3D VMAT Verification
PLOS ONE | DOI:10.1371/journal.pone.0166767 November 21, 2016 9 / 19
described in previous section. Although in the Figs 3 and 4, only results for prostate VMAT
plan B are shown, the following considerations can be extended to the other plans. As
expected, the more pronounced discrepancies between MC log calculation and film were
found for the coarse discretization, as it is shown in the left column of Fig 3. Furthermore, the
different level of discretization between coarse and fine also had an impact on the procedure
for obtaining the dose distribution experimentally reconstructed (QuAArC solution) from the
measurements in the QuAArC phantom, as it can be observed in the right column of Fig 3.
This shows how our model could establish the required level of discretization to obtain an ade-
quate VMAT verification based on MC simulation of log files free-dependent on detection
density. It is important to remark that these differences would not have been so evident
whether a lower density detection implemented in other VMAT verification systems would
have been employed. On the other side, the consistency of these results provides confidence on
our model.
After experimental adjustment, the more relevant MU changes were found at the same arc
locations for both discretization levels, showing the procedure does not work randomly along
the whole arc, but the algorithm proposed bigger changes where the differences between theo-
retical and experimental values were higher. Also, as expected, the global change was more
Fig 4. QuAArC system reports for fine and coarse discretization. Comparison between original and experimentally adjusted solutions for both
discretizations. Angular MU distributions from the original log file MC simulation and the experimentally adjusted with QuAArC (a) and the corresponding
MU differences for coarse discretization (b). The same for fine discretization (d and e). DVHs comparison between Monaco TPS solution, MC log file
simulation and QuAArC reconstructed solution, for coarse (c) and fine discretization (f). All for prostate VMAT plan B.
doi:10.1371/journal.pone.0166767.g004
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uniformly distributed along the arc for the fine (Fig 4(d) and 4(e)) than for the coarse discreti-
zation (Fig 4(a) and 4(b)). This latter showed that the MU adjustment was mainly carried out
with the lateral contribution from the contiguous CPs, what was our goal in order to achieve a
reconstruction of the accumulated MU in the log file with the information continuously regis-
tered in the film.
According the comparison followed in Fig 3 with the rest of measurements in the phantom,
the finer approach provided a more reliable reconstructed DVH solution (Fig 4(c)–4(f)), and
was considered as the necessary option in QuAArC verification procedure for this case.
Although for this case, coarse QuAArC approach provided a similar DVH solution that could
have also been approved, the same was not observed for the rest of analyzed cases. Anyway, the
evaluation of more clinical cases would be necessary to prove what level of discretization could
be enough for an efficient verification procedure in shorter times. With this work, we suggest
that this kind of studies with verification systems different to the model proposed here, could
be biased due to the use of lower detection density and to different spatial distribution.
Proof of concept of the experimental feedback process
As a part of the proof of concept of the model, comparisons of outer and inner film scroll dose
distributions with the ones obtained by means of QuAArC system were carried out (Figs 5–7),
Fig 5. Proof of concept of the experimental feedback process for the prostate case from Monaco. Film and QuAArC dose distributions,
corresponding percent dose differences and gamma analysis are shown for outer and inner scrolls for VMAT Plan A (first and second rows, respectively),
and the same for VMAT Plan B (third and fourth rows).
doi:10.1371/journal.pone.0166767.g005
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Fig 6. Proof of concept of the experimental feedback process for the H&N case from Monaco. Film and QuAArC dose distributions, corresponding
percent dose differences and gamma analysis are shown for outer and inner scrolls of VMAT Plan A (first and second rows, respectively), and the same
for IMRT Plan B (third and fourth rows).
doi:10.1371/journal.pone.0166767.g006
Fig 7. Proof of concept of the experimental feedback process for the prostate and H&N VMAT plans
from Pinnacle. Film and QuAArC dose distributions, corresponding percent dose differences and gamma
analysis are shown for outer and inner scrolls.
doi:10.1371/journal.pone.0166767.g007
3D VMAT Verification
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for prostate case and H&N case, respectively. The color code used to represent the percent
dose difference matrices was set according to the passing rate values presented in Table 1 (%
pixels having a dose within 3%). Gamma analysis based on 2% DD/2mm DTA criteria was
also included. All QuAArC scrolls showed a high agreement with the measured film scrolls for
both, percent dose differences and gamma analysis, which values are given in table 1. Since
there is always a limitation regarding the discrete calculation, even with the fine discretization
under consideration, minor differences were assumed. Anyway, these small differences
observed were mostly located outside the treatment field or at the edges. Note that this com-
parison was carried out with the MC scrolls resolution (1 x 0.7854 mm2 for outer scroll and 1 x
0.3523 mm2 for inner scroll) obtained after the dose recruitment described in Materials and
methods section.
Table 1 shows a summary of passing rates for dose differences within 3% and global gamma
index with 2%/2 mm criteria obtained for MC simulations of fine log discretization (MC
LOG) and the corresponding QuAArC solutions after experimentally adjustment. The values
for the absolute dosimetry performed with ion chamber in QuAArC phantom and the
obtained from MC LOG and QuAArC solutions, after experimental adjustment, were also
included in Table 1. For Monaco plans, all MC LOG and QuAArC absolute dose values were
obtained with less than 1.25% of statistical uncertainty, and agreed with the experimental mea-
surement within 2%. For Pinnacle plans, the prostate VMAT case agreed well within the 3% in
absolute dose, while the H&N VMAT plan presented a higher deviation, although, it was not
significant for reconstructing the DVH, so we considered this result acceptable. For this case, a
location less exposed to high dose gradient should have been chosen for the absolute dose
point measurement in order to have a more reliable experimental value. For further evaluation
one should consider repeat this measurement, but the high agreement with film and improved
results for QuAArC compared to the MC LOG, were considered to be sufficiently acceptable
to obtain a reconstructed DVH, which better estimates the delivered dose. In general, the pass-
ing rates improved for QuAArC solution after experimental adjustment regarding the MC
LOG in both, 3% dose difference and gamma analysis. For QuAArC solution, all evaluated
plans had a γ index < 1 passing rate greater than 90% using 2%/2 mm criteria in both scroll
regions (outer and inner) and greater than 95% most of them. For 3%/3 mm criteria, passing
rates were greater than 97%, in all cases. As expected, this same test based on coarse discretiza-
tion approach provided worse passing rates.
Table 1. Summary of absolute doses, percent dose differences and gamma index passing rates for all evaluated treatment plans.
Plan Absolute dose (Gy) (% deviation) Dose difference passing rates (%) (<3%) γ-index passing rates (%) (2%/2mm)
Outer scroll Inner scroll Outer scroll Inner scroll
CC04 MC LOG QuAArC MC LOG QuAArC MC LOG QuAArC MC LOG QuAArC MC LOG QuAArC
Prostate Case from Monaco
A 2.48 2.51 (1.21) 2.53 (2.02) 92.95 91.94 78.33 84.85 90.77 90.12 87.91 93.19
B 2.45 2.42 (-1.22) 2.45 (0.00) 92.78 95.48 80.83 91.19 88.34 92.66 89.94 97.09
H&N Case from Monaco
A 2.02 2.01 (-0.49) 2.06 (1.98) 96.89 97.61 89.52 96.04 96.28 97.45 91.19 98.18
B 2.06 2.07 (0.48) 2.07 (0.48) 97.53 98.16 93.16 94.51 97.87 98.40 96.84 97.60
Prostate case from Pinnacle
- 3.67 3.56 (-3.00) 3.57 (-2.72) 99.05 99.53 97.55 96.63 96.51 90.53 95.45 96.62
H&N case from Pinnacle
- 2.03 2.13 (4.93) 2.16 (6.40) 77.08 90.78 80.43 94.16 78.64 91.90 82.78 97.84
doi:10.1371/journal.pone.0166767.t001
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For the IMRT H&N plan B (4th row of Table 1), the results were practically the same for
MC LOG and QuAArC solution, meaning that our model did not modify the MUs when the
delivery was static.
QuAArC application to clinical cases
In the case of considering our QuAArC model as a pre-treatment VMAT verification system,
we propose the reconstructed DVH by means of our model as the relevant metric for accep-
tance criteria of the treatment planning under evaluation (Figs 8 and 9).
Fig 8. DVHs comparison between Monaco TPS solution and QuAArC reconstructed solution. VMAT plan A (a) and B (b), for the Prostate
case and VMAT plan A (c) and IMRT plan B (d), for the H&N case.
doi:10.1371/journal.pone.0166767.g008
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Starting the discussion with the cases from Monaco (Fig 8), it is important to remark that
the commented agreement for the static IMRT case was also observed in the DVHs compari-
son with Monaco TPS solution (Fig 8(d)), since Monaco calculation is strongly based on MC,
what is similar to our full MC model. The minor discrepancies in OARs could be due to the
different consideration of beam modifiers contribution to the dose.
In the static plan, the MC log simulation represented the measurement well enough, but it
was not the same for VMAT plans, as it can be seen in Table 1. MU adjustment approach pro-
posed in our system showed to be necessary for exhaustive dynamic treatment verification.
Apart from the IMRT commented above, the VMAT cases which were not accepted with
Delta4 verification, were well adjusted by our model (plan A in Figs 5 and 6), although the
resulting DVHs (Fig 8(a)–8(c)) showed to be significantly different to the planning with
Monaco TPS, while the DVH corresponding to the VMAT plan B accepted with Delta4 (Fig 8
(b)) showed to be very similar to the Monaco solution. These results obtained with our model
showed to be in tune with Delta4 verification. In any case, considering the two uncertainties
pointed out in the Introduction section, it could be estimated that the potential discrepancies
involved in the continuous delivery of a discrete calculation are more significant than those
due to the dose calculation accuracy.
For the cases planned with Pinnacle TPS by implementing a non MC-based algorithm dose
calculation, the same DVHs comparison is presented on Fig 9. These plans showed more dif-
ferences for the OARs, as opposite to what was observed for Monaco plans. This discrepancy is
assumed to be due to the different algorithms used for dose calculation. Pinnacle can be under-
estimating the transmission contribution from the MLC to the final dose. Anyway, in general,
the DVHs obtained with QuAArC for the target planning volumes showed similar results to
the plans calculated with Pinnacle, likely because these plans were approved by COMPASS.
Otherwise, more differences could be found.
It is necessary to remark that all these results in Figs 5–7 and Table 1, indicated that the
model developed was robust and consistent, and were included in this work only to prove the
feasibility of the novel feedback procedure and to provide confidence about the experimental
reconstruction of DVHs (Figs 8 and 9). In fact, these DVHs should be considered as the main
evaluation metric for a potential use of QuAArC as a VMAT verification system.
Conclusions
The developed QA model allowed the verification of VMAT treatments with high accuracy
provided by the MC explicit radiation transport simulation of the actual delivery treatment
Fig 9. DVHs comparison between Pinnacle TPS solution and QuAArC reconstructed solution.
Prostate VMAT plan (left) and H&N VMAT plan (right).
doi:10.1371/journal.pone.0166767.g009
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parameters from the log files, and with the high spatial resolution provided by film dosimetry.
The proposed model is able to control and reduce the uncertainties involved in complex
dynamic techniques, what is useful for further studies about VMAT efficiency versus static
IMRT techniques for specific clinical cases, and also for carrying out the linac commissioning
and evaluation of other QA systems.
This work was not focused to make a comprehensive study on the different verification sys-
tems and dose calculation algorithms for dynamic techniques. Anyway, few clinical cases were
evaluated to check the feasibility of our model. On one hand, for those cases which were
approved with Delta4 and COMPASS, QuAArC system provided similar DVHs to the solu-
tions from TPSs corresponding to planning targets, Monaco and Pinnacle, respectively. More
important disagreement was observed for DVHs corresponding to OARs in the cases from
Pinnacle/COMPASS. The dose calculation uncertainty using Monaco TPS was observed to be
not as relevant as the uncertainty linked to the dynamic delivery. However, greater differences
were found when QuAArC solutions were compared with Pinnacle TPS, where this uncer-
tainty, linked to the dose calculation accuracy, also added discrepancies, as expected. On the
other hand, for those cases which were not previously approved with Delta4 from Monaco
TPS solutions, QuAArC did show a greater disagreement for DVHs of PTVs. All these results
proved that QuAArC system was consistent with expected results, what support the viability of
the model for this kind of studies.
It is important to note that the QuAArC phantom based on film can be implemented apart
from full MC log calculation, whether the TPS is able to provide individualized CP dose contri-
bution. This would lead to more efficient computational times for routine pre-treatment verifi-
cation, although with our approach based on MC calculation, the results were more reliable
and, in fact, they were ready at time of film processing stage.
Besides the effect of dose calculation accuracy of a dynamic technique, this work was mainly
focused on the evaluation of the effect of the detection density level and its location in a specific
phantom to obtain a more reliable DVH. This could be useful to detect potential wrong deci-
sions based on the results from commercial VMAT verification systems, due to mismatching
between control points used for dose reconstruction and the detector locations. This latter
aspect is being evaluated by our group in a current project in which, we would like to include
as many verification systems as possible. QuAArC system is also being adapted for 4D verifica-
tion to adequately verify treatments such as stereotactic body radiotherapy (SBRT) for lung
cancer.
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